Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal …
Among these therapies, the tyrosine kinase inhibitors (TKI) sorafenib and sunitinib were the first novel therapies approved for advanced RCC in Europe in 2006. Since then, many more TKIs …
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in
2025年3月22日 · Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination therapy is emerging as a major therapeutic strategy for advanced clear cell renal …
Immunotherapy Strategies After Immune Checkpoint Inhibitor …
5 天之前 · First-line treatment in metastatic renal cell carcinoma (mRCC) consists of an anti−PD-1 antibody administered in combination with either a CTLA-4 inhibitor or an oral vascular …
Reviewing RCC Treatment Choices After Progression With IO/TKI
4 天之前 · During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity. Decrease or stabilization in …
Long-Term Data on IO/IO in RCC Shows Intriguing Results for …
4 天之前 · It was the only dual immunotherapy (IO) trial in the front line, compared with 3 other regimens combining IO with tyrosine kinase inhibitor (TKI). It had 3 primary end points of …
Activity of lenvatinib-based therapy in previously treated patients ...
6 天之前 · Lenvatinib is a potential treatment after immunotherapy and TKI in refractory RCC. ABSTRACT. Background and Objective. Lenvatinib’s activity after immune checkpoint …
Tyrosine kinase inhibitors and immunotherapy combinations in renal …
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular …
晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识（2022）
2022年5月19日 · 一项回顾性队列研究对接受tki治疗的晚期rcc 患者数据进行分析，评估6个相关基因突变状态（bap1、pbrm1、tp53、tert、kdm5c 和setd2）与肿瘤特异性结局之间的相关性， …
Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal …
4 天之前 · In the treatment of metastatic RCC (mRCC), cabozantinib, a potent TKI targeting VEGFR and MET, has demonstrated an acceptable therapeutic effect . In the previous study, …
Temporary cessation versus continued TKI therapy for RCC
2023年3月15日 · Tyrosine kinase inhibitor (TKI) treatment showed improved overall survival (OS) in patients with advanced or metastatic renal cell carcinoma (RCC).